A 12-Week, Double-Blind, Placebo-Controlled, Trial of Duloxetine Versus Placebo in the Treatment of Binge Eating Disorder and Comorbid Depressive Disorder.
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 入组人数
- 40
- 试验地点
- 1
- 主要终点
- Binge Eating Days
研究概览
简要总结
The purpose of this research study is to test the safety of duloxetine and see what effects (good and bad) it has on the subject's binge eating disorder and comorbid depressive disorder (depression occurring with binge eating disorder) compared to placebo (inactive pill).
详细描述
This is a 12-week, double blind, randomized, placebo-controlled, parallel-group, flexible-dose study of duloxetine 60-120 mg/day in patients with BED and comorbid depressive disorders. Patients will be randomly assigned to either duloxetine 30 mg capsules or matching placebo at the baseline visit. The initial dose of study medication will be one 30 mg duloxetine capsule/day or placebo with a planned increase to 60 mg/day (2 X 30 mg) or matching placebo at the end of week 1. Further dose increases of 30 mg up to 120 mg/day will be allowed after the end of week two based on the investigators' assessment of efficacy and tolerability. Dosing will be either once per day or twice a day depending on tolerability. Patient visits will occur at screening and baseline and at the end of weeks 1, 2, 4, 6, 8, 10, and 12. Study drug will be tapered by 30 mg every 3 days at the end of the study.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Triple (Participant, Care Provider, Investigator)
入排标准
- 年龄范围
- 18 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- •Women who are pregnant, breastfeeding, or of childbearing potential who are not using a medically acceptable, effective method of birth control. Women of childbearing potential include all pre-menopausal women biologically capable of becoming pregnant or contributing a fertilizable ovum. Medically acceptable methods of birth control include oral contraceptives, an intrauterine device, use of two combined barrier methods, or surgical sterilization.
- •Patients who display significant risk for suicide.
- •Patients who have received psychotherapy or behavioral therapy from a mental health professional as a part of previous treatment for MDD or obesity for at least 3 months prior to randomization.
- •A DSM-IV diagnosis of alcohol or substance abuse or dependence, bulimia nervosa, or anorexia nervosa within the 6 months prior to randomization.
- •Patients with a lifetime DSM-IV history of a psychotic disorder, a bipolar disorder, or dementia.
- •Patients with a history of psychosurgery
- •Patients with an Axis II disorder (personality disorders such as schizotypal, borderline, or antisocial), which might interfere with a diagnostic assessment, treatment, or compliance.
- •Patients with clinically unstable medical disease.
- •Patients with hepatic insufficiency
- •Patients with end-stage renal disease or severe renal impairment
- •Patients with a history of seizures, including febrile seizures in childhood.
- •Patients requiring treatment with any drug which might interact adversely with or obscure the action of the study medication.
- •Patients with a known hypersensitivity to duloxetine or any of the inactive ingredients of duloxetine (Cymbalta).
- •Patients with uncontrolled narrow-angle glaucoma.
- •Patients with clinically relevant abnormal laboratory results, specifically including hypokalemia.
- •Patients who have received monoamine oxidase inhibitors, tricyclics, antipsychotics, lithium, or fluoxetine within four weeks prior to randomization.
- •Patients who have received other psychoactive medications (including appetite suppressants) or any anti-obesity medications within one week prior to randomization.
- •Patients who have received investigational medications or depot neuroleptics within three months prior to randomization.
- •Patients previously enrolled in this study or who have previously been treated with duloxetine.
- •Subject considered by the investigator as unable to be followed up throughout the entire duration of the study.
- •Patients taking medications that inhibit the P450-2D6 hepatic isoenzyme
研究组 & 干预措施
Duloxetine Group
Start with 30 mg duloxetine hydrochloride capsule/day to be increased up to 120 mg per day.
干预措施: Duloxetine (Drug)
Placebo Group
Sugar pill with matching dosage as Duloxetine
干预措施: Placebo (Drug)
结局指标
主要结局
Binge Eating Days
时间窗: 12 weeks
The mean number of binge days (days when the participant had one or more binge eating episodes) per week in the interval between visits (total number of binge days in the interval divided by number of days in the interval, then multiplied by 7).
次要结局
- Weekly Episodes(12 weeks)
研究者
Erik Nelson
Erik B. Nelson, MD & Susan McElroy, University of Cincinnati & Lindner Center of HOPE
University of Cincinnati